Filing Flows › 8-K events › HCW Biologics
HCW Biologics: entry into a material definitive agreement
Form 8-K filed Nov 5, 2026 · items 1.01, 7.01, 8.01
Entry into a material definitive agreementHCW Biologics Secures up to $10.0 Million in Cash Through Debt Financing
What the filing says
On November 3, 2026, HCW Biologics Inc. (the “Company”) entered into a Notes Purchase Agreement (the “Purchase Agreement”) with Streeterville Capital, LLC (the “Lender”), providing for the issuance of two secured promissory notes: (i) a Promissory Note A-1 in the original principal amount of $3.2 million (the “A-1 Note
ScaleThe filing names $10.0M: 18× HCW Biologics' annual revenue ($542K, four times the latest quarter).
Read the filing on SEC EDGAR →
What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 8.01: +0.1% next session across 44,881. Every item ranked →
What this kind of filing means
Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.
HCW Biologics at a glance
HCW Biologics, Q2 2026: revenue $136K (21× year over year). The chart follows the revenue to costs, profit and cash.
HCW Biologics: every quarter, Q/Q and Y/Y, holders and guidance →
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.